or Try an Advanced Search...

    Treprostinil Stocks List

    Symbol Grade Name % Change
    ASND D Ascendis Pharma A/S 0.25
    LQDA D Liquidia Technologies, Inc. -3.37
    UTHR B United Therapeutics Corporation -0.67
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Hypertension Pulmonary Arterial Hypertension Biotechnology Life Sciences Alcohol Biopharmaceutical Blastoma Brain Cancer Breakthrough Therapy Bupivacaine Chemical Compounds Chronic And Life Threatening Conditions Clinical Trial Diabetes Disease Drug Therapies Growth Hormone Growth Hormone Deficiency Growth Hormone Therapy Hepatitis C

    Related ETFs - A few ETFs which own one or more of the above listed Treprostinil stocks.

    Symbol Grade Name Weight
    MEDI D Harbor Health Care ETF 16.82
    PJP A PowerShares Dynamic Pharmaceuticals 4.4
    BBP C BioShares Biotechnology Products Fund 4.33
    SYNB B Putnam BioRevolution ETF 3.93
    FBT D First Trust Amex Biotech Index Fund 3.67
    View all Treprostinil ETFs...
    Compare ETFs
    Compare BBP to FBT Compare MEDI to PJP Compare PJP to BBP

        Treprostinil Stocks Recent News

        Date Stock Title
        May 10 UTHR Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates
        May 10 UTHR Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
        May 10 LQDA Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
        May 9 UTHR CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
        May 9 ASND Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024
        May 8 UTHR Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
        May 8 ASND An Update On Ascendis Pharma's Path To Profitability
        May 7 UTHR Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
        May 7 LQDA Liquidia Corporation to Present at BofA Securities Health Care Conference 2024
        May 7 LQDA Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024
        May 7 UTHR Best Value Stocks to Buy for May 7th
        May 7 UTHR Insider Sale: Director Judy Olian Sells Shares of United Therapeutics Corp (UTHR)
        May 7 UTHR Insider Sale: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR)
        May 6 UTHR United Therapeutics (UTHR) is an Incredible Growth Stock: 3 Reasons Why
        May 6 ASND Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript
        May 6 UTHR United Therapeutics Corporation (UTHR) Hits Fresh High: Is There Still Room to Run?
        May 4 ASND Ascendis Pharma A/S (ASND) Q1 2024 Earnings Call Transcript
        May 4 ASND Ascendis Pharma First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
        Related Industries: Biotechnology
        Related Stock Lists: Hypertension Pulmonary Arterial Hypertension Biotechnology Life Sciences Alcohol Biopharmaceutical Blastoma Brain Cancer Breakthrough Therapy Bupivacaine Chemical Compounds Chronic And Life Threatening Conditions Clinical Trial Diabetes Disease Drug Therapies Growth Hormone Growth Hormone Deficiency Growth Hormone Therapy Hepatitis C
        Treprostinil

        Treprostinil (marketed under the trade names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation) is a vasodilator that is used for the treatment of pulmonary arterial hypertension. Treprostinil is a synthetic analog of prostacyclin (PGI2).
        The inhaled form of treprostinil was approved by the FDA in July 2009 and is marketed as the trade name Tyvaso.

        More about Treprostinil
        Browse All Tags